Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual growth rate in the double digits from today over the next several years, with the market reaching $100 billion to $130 billion in the early 2030s.Today, Eli Lilly and Novo Nordisk dominate with their well-known treatments: Lilly makes tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound fo ...

Core Viewpoint - Pfizer's CEO indicates that tariffs and uncertainty from the Trump administration are hindering the company's ability to make significant investments in the US [1][2]. Group 1: Impact of Tariffs on Investments - CEO Albert Bourla stated that the absence of tariffs and a stable environment would enable Pfizer to make "tremendous investments" in both R&D and manufacturing in the US [2]. - Bourla emphasized that during uncertain times, companies, including Pfizer, are controlling costs and being "very frugal" with investments to remain prepared for any eventualities [2]. - Pfizer currently operates 13 manufacturing sites in the US, which are functioning at good capacity, but the company is prepared to transfer manufacturing from overseas sites if necessary [3]. Group 2: Financial Implications of Tariffs - Pfizer's finance chief, Dave Denton, projected that the existing tariffs would cost the company approximately $150 million by 2025 [4]. - Although pharmaceutical products were initially exempt from the 10% tariffs announced by Trump, there are plans to impose tariffs on pharmaceuticals to encourage companies to relocate manufacturing to the US [4][5]. Group 3: Industry Reactions and Competitor Actions - AstraZeneca's CEO mentioned that the company could consider shifting some manufacturing to the US if pharmaceutical tariffs are implemented [6]. - Merck has begun construction on a $1 billion commercial production facility in Delaware, highlighting its commitment to US manufacturing [7]. - Investor Mark Cuban warned that drug prices from his company could rise if tariffs on India are enforced [7].

Core Insights - Pfizer (PFE) shares increased by 3% following the release of Q1 earnings that significantly exceeded expectations, although the stock has declined 10% year-to-date [1][6] - The company is trading near multi-year lows at approximately $20 per share, which may attract investors looking for a rebound [2][6] Q1 Results - Pfizer reported Q1 earnings of $0.92 per share, surpassing EPS expectations of $0.64 by 43% and up from $0.82 in the same quarter last year [3][4] - Q1 sales totaled $13.71 billion, falling short of estimates of $13.83 billion and down from $14.87 billion year-over-year [4] Full-Year Guidance - Pfizer reaffirmed its fiscal 2025 guidance, projecting revenues between $61 billion and $64 billion, with Zacks projections at $63.48 billion [7] - The company expects adjusted FY25 EPS to be in the range of $2.80 to $3.00, with the Zacks Consensus at $2.99 [7] Valuation Metrics - Pfizer's stock is trading at a price-to-forward earnings ratio of 7.7X, significantly lower than its decade-high of 20.1X and below the S&P 500's 21.3X [8] - The stock is also trading at a discount compared to the Zacks industry average of 16.4X [8] Dividend Information - Pfizer offers an annual dividend yield of 7.46%, which is substantially higher than the industry average of 2.51% and the benchmark's 1.33% [10] - The company has increased its dividend for 16 consecutive years, despite losing its dividend aristocrat status during the 2008 financial crisis [10] Market Sentiment - Following the Q1 report, Pfizer holds a Zacks Rank 2 (Buy), with earnings estimate revisions for FY25 and FY26 trending upward [12] - The company's strong performance in exceeding EPS expectations and its cost-saving initiatives may enhance its valuation and attract long-term investors [13]

Financial Data and Key Metrics Changes - For Q1 2025, Pfizer reported revenues of $13.7 billion, a decline of 6% operationally, primarily due to lower Paxlovid revenues and changes in the IRA Medicare Part D redesign [24][25][27] - Diluted EPS for Q1 2025 was $0.52, with adjusted diluted EPS at $0.92, exceeding expectations due to strong gross margin and cost management [25][28] - Adjusted gross margin expanded to approximately 81%, driven by favorable crude royalties, despite an unfavorable product mix [27] Business Line Data and Key Metrics Changes - The Vyndaqel family of products showed robust growth, although competition from new entrants is anticipated [19] - Nurtech revenue grew 40% operationally in Q1, reflecting strong demand and effective engagement with healthcare professionals [19] - The oncology portfolio, including TACCEV and LOBRENA, demonstrated significant growth, with TACCEV growing 25% and LOBRENA growing 39% operationally [20][21] Market Data and Key Metrics Changes - International operations returned to growth in Q1 2025, driven by disciplined focus on key growth drivers [18] - The U.S. market showed strength in key products, contributing to overall performance despite challenges from Paxlovid and other products [25][27] Company Strategy and Development Direction - Pfizer's strategic priority for 2025 includes improving R&D productivity and advancing its pipeline with a focus on potential blockbuster products [7][9] - The company is committed to building its cardiometabolic pipeline and exploring partnerships or acquisitions to enhance its offerings [8] - A refined commercial model has been implemented to prioritize impactful products and regions, enhancing operational efficiency [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating the volatile external environment, emphasizing strong relationships with government leaders [6] - The company reaffirmed its 2025 guidance, expecting revenues between $61 billion and $64 billion and adjusted diluted EPS between $2.8 and $3 [34] - Management highlighted ongoing productivity improvements and cost management as key to enhancing shareholder value [22][30] Other Important Information - Pfizer's capital allocation strategy includes maintaining and growing dividends while investing in R&D and pursuing share repurchases [29] - The company anticipates approximately $7.7 billion in savings by the end of 2027 from various cost improvement initiatives [31] Q&A Session Summary Question: Dividend commitment amidst tariff uncertainties - Management reiterated that the dividend remains a critical component of their capital allocation strategy, emphasizing improved operating margins to support cash flow [39][43] Question: Stability of COVID business - Management indicated that Paxlovid utilization trends closely follow infection rates, with expectations of multiple COVID waves throughout the year [41][45] Question: Future obesity asset profile - Management confirmed a commitment to obesity treatment, focusing on differentiated oral medicines and addressing significant unmet needs in the market [52][55] Question: Impact of tariffs on manufacturing investments - Management expressed that certainty regarding tariffs would encourage significant investments in R&D and manufacturing in the U.S. [93][99] Question: Cost realignment program and guidance - Management stated that while $1.2 billion in additional savings is expected, most will be realized in 2026 and 2027, with some savings from R&D expected this year [102][105]

Albert Bourla, chairman and CEO of Pfizer, speaks at The Wall Street Journal’s Future of Everything Festival in New York City, U.S., May 22, 2024.Pfizer CEO Albert Bourla on Tuesday said uncertainty around President Donald Trump's planned pharmaceutical tariffs is deterring the company from further investing in U.S. manufacturing and research and development. Bourla's remarks on the company's first-quarter earnings call came in response to a question about what Pfizer wants to see from tariff negotiations t ...

Core Viewpoint - Pfizer reported mixed first-quarter results for 2025, with adjusted earnings per share of 92 cents exceeding estimates but revenues of $13.72 billion falling short of expectations, reflecting a year-over-year decline of 8% [1][2][15]. Revenue Performance - Total revenues were $13.72 billion, down 8% year-over-year, missing the Zacks Consensus Estimate of $13.89 billion, with operationally a decrease of 6% and a negative currency impact of 2% [2]. - International revenues increased by 4% operationally to $5.34 billion, while U.S. revenues declined by 12% to $8.37 billion [3]. Product Segment Analysis - Primary Care segment sales fell 20% operationally to $5.7 billion, with Eliquis sales declining 4% to $1.92 billion due to pricing pressures from the Inflation Reduction Act [4][5]. - Specialty Care sales rose 6% to $4.0 billion, driven by Vyndaqel family revenues increasing by 33% to $1.49 billion [4][10]. - Oncology sales increased by 7% to $3.76 billion, with Padcev sales rising 25% to $426 million, while Ibrance revenues declined by 6% to $977 million [4][12][13]. Key Product Performance - Paxlovid revenues dropped 75% year-over-year to $491 million, missing estimates [8]. - Comirnaty sales rose 62% year-over-year to $565 million, exceeding expectations [7]. - The RSV vaccine, Abrysvo, recorded sales of $131 million, down 6% year-over-year, missing estimates [9]. Cost Management - Adjusted selling, informational, and administrative expenses decreased by 12% to $3.01 billion, while adjusted R&D expenses also fell by 12% to $2.17 billion [3]. 2025 Guidance - Pfizer reaffirmed its 2025 guidance, projecting total revenues between $61.0 billion and $64.0 billion, with adjusted earnings per share expected in the range of $2.80 to $3.00 [14][16]. Market Context - Pfizer's stock has declined 11.7% year-to-date, contrasting with a 1.5% increase in the industry [16]. - The company faces challenges from declining COVID-19 product sales and potential patent expirations impacting key products from 2026 to 2030 [17]. Strategic Outlook - Pfizer anticipates that non-COVID drug sales and new product contributions will drive revenue growth in 2025, alongside cost-cutting measures expected to yield savings of $7.7 billion by the end of 2027 [20].

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 250 points on Tuesday.The Dow traded up 0.70% to 40,507.41 while the NASDAQ rose 0.30% to 17,417.49. The S&P 500 also rose, gaining, 0.37% to 5,548.98.Check This Out: Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2Leading and Lagging SectorsMaterials shares jumped by 0.6% on Monday.In trading on Monday, consumer discretionary fell by 0.5%.Top HeadlineShares of Pfizer Inc. PFE gained around 3% on Tuesday ...

Francesca DeMartino Chief Investor Relations Officer, Senior Vice President First Quarter 2025 Earnings Teleconference April 29, 2025 1 Introduction First Quarter 2025 Earnings 2 Forward-Looking Statements and Non-GAAP Financial Information First Quarter 2025 Earnings 3 • Our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statem ...

Pfizer (PFE) Q1 2025 Earnings Call April 29, 2025 10:00 AM ET Company Participants Francesca DeMartino - SVP & Chief Investor Relations OfficerAlbert Bourla - Chairman & CEODave Denton - EVP & CFOAamir Malik - Executive VP & Chief U.S. Commercial OfficerAlexandre de Germay - Executive VP & Chief International Commercial OfficerChris Boshoff - Chief Scientific Officer and President, Research & DevelopmentAndrew Baum - Chief Strategy & Innovation Officer, Executive VPUmer Raffat - Senior Managing DirectorChri ...

Pfizer (PFE) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.82 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 43.75%. A quarter ago, it was expected that this drugmaker would post earnings of $0.48 per share when it actually produced earnings of $0.63, delivering a surprise of 31.25%.Over the last four quarters, the company has surp ...